Risk group-Intermediate risk Posts on Medivizor
Navigation Menu

Risk group-Intermediate risk Posts on Medivizor

Treatment of adolescents and young adults with acute lymphoblastic leukemia by a pediatric-inspired therapy

Treatment of adolescents and young adults with acute lymphoblastic leukemia by a pediatric-inspired therapy

Posted by on Mar 13, 2020 in Leukemia | 0 comments

In a nutshell The study investigated whether a pediatric (designed for children) therapy for acute lymphoblastic leukemia (ALL) can treat adolescents and young adults (AYA) with standard-risk (SR) ALL. The main finding was that a full pediatric therapy could effectively treat such patients. Some background There are major differences between therapies...

Read More

A long term follow-up study of young people with acute lymphoblastic leukemia.

A long term follow-up study of young people with acute lymphoblastic leukemia.

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study examined the long-term effectiveness of different treatment strategies for acute lymphoblastic leukemia (ALL) in young people. This study concluded that augmented treatment for rapid early responders was most beneficial, with improved survival at 10 years.  Some background ALL is a cancer of the bone marrow. It leads to...

Read More

Is busulfan a useful drug to improve successful transplantation in the treatment of acute leukemia?

Is busulfan a useful drug to improve successful transplantation in the treatment of acute leukemia?

Posted by on Jun 26, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of using busulfan to delete blood cancer cells from the system before replacing them with normal cells in the treatment of leukaemia. The study found that busulfan therapy was effective in removing blood cancer cells before replacement, in the treatment of high-risk acute leukaemia. Some background Acute...

Read More

A review of CAR-T cell therapy for CLL

A review of CAR-T cell therapy for CLL

Posted by on Jan 27, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed CAR-T cell therapy, a new type of immunotherapy, for chronic lymphocytic leukemia (CLL). Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In this treatment, immune cells (the T-cells) are removed from the blood. The T-cells are then genetically modified...

Read More

An analysis comparing reduced-intensity conditioning and myeloablative therapy for CLL

An analysis comparing reduced-intensity conditioning and myeloablative therapy for CLL

Posted by on Dec 30, 2017 in Leukemia | 0 comments

In a nutshell This study analyzed the results of 37 studies comparing myeloablative therapy and reduced intensity conditioning (RIC) before stem cell transplantation in patients with chronic lymphocytic leukemia (CLL). This study concluded that RIC was associated with lower mortality and better survival compared to myeloablative therapy. Some...

Read More